ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2024; 15(1):54-67. doi:10.7150/jca.88261 This issue Cite
Review
Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy
Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
Abstract
Mucin1 is a highly glycosylated type 1 transmembrane mucin that ranks second among 75 tumor-related antigens published by the National Cancer Institute, and has been identified as a possible therapeutic target over the past 30 years. MUC1 plays an important role in malignant transformation and disease evolution, including cell proliferation, survival, self-renewal, and metastatic invasion. MUC1 has been shown to interact with diverse effectors such as β-catenin, receptor tyrosine kinases, and cellular-abelsongene, which are of importance in the pathogenesis of various malignant tumors. Targeting MUC1 has been shown to be an effective way to induce tumor cell death in vivo and in vitro models. In recent years, a number of therapeutic strategies targeting MUC1 have been developed and their value for tumor therapy have been demonstrated experimentally. This review summarizes recent findings on the structure of MUC1, its expression in different tumors and its involved mechanism pathways, with emphasis on new progress in cancer therapy which related MUC1 in the past decade and evaluates their therapeutic effect.
Keywords: MUC1, cancer, immunotherapy, targeted therapy, combination therapy
Citation styles
